• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, August 17, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

New approach on the use of big data in clinical decision support

Bioengineer by Bioengineer
October 3, 2018
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Nuno Agostinho, iMM.

A new computational approach that allows the identification of molecular alterations associated with prognosis and resistance to therapy of different types of cancer was developed by the research grould led by Nuno Barbosa Morais, Group Leader at Instituto de Medicina Molecular João Lobo Antunes (iMM; Portugal), and now published open access in Nucleic Acids Research*.

Cancer cells are characterised by perturbations in the regulation of genes and, in particular, by alterations in alternative splicing, a process by which the same gene can originate different proteins. Some of those alterations are associated with different malignant features of cancer and its resistance to treatment but vary from tumour to tumour. "Each patient hosts a different cancer, so that scientists and clinicians need molecular information about many individuals to, supported by data, understand disease mechanisms, assess prognosis and make predictions on the best treatment for each patient based on their tumour's molecular profile", explains Nuno Barbosa Morais.

"We have created a software that, by analysing large databases with clinical and splicing information for thousands of tumours, detects patterns of similarities between different cases and allows, for instance, to identify the relation of each molecular alteration with patient survival, for more than thirty types of cancer. In practice, the program allows to quickly convert a lot of genome-wide data into biological information with clinical potential", explains Nuno Saraiva Agostinho, first author of the study and student of the PhD programme CAML (Centro Académico de Medicina de Lisboa, da Faculdade de Medicina da Universidade Lisboa).

"Thanks to this approach, we have already identified a possible mechanism of resistance to chemotherapy in colorectal cancer that we are now investigating, in an international collaboration that we are leading. We have also identified a new prognostic marker in breast cancer that we will now study, teaming up with other iMM colleagues", highlights Nuno Barbosa Morais, who leads the lab and has supervised the study.

###

This work was funded by the European Molecular Biology Organisation (EMBO) and the Portuguese Fundação para a Ciência e a Tecnologia (FCT).

*Saraiva-Agostinho, N, Barbosa-Morais, N.L. (2018) psichomics: graphical application for alternative splicing quantification and analysis. Nucleic Acids Research. gky888, https://doi.org/10.1093/nar/gky888

Media Contact

Inês Domingues
[email protected]
351-915-456-900

https://imm.medicina.ulisboa.pt/en/

Related Journal Article

http://dx.doi.org/10.1093/nar/gky888

Share12Tweet7Share2ShareShareShare1

Related Posts

Loneliness Fuels Depression in Cancer Survivors

Loneliness Fuels Depression in Cancer Survivors

August 16, 2025
Nab-Paclitaxel Combo Outperforms Gemcitabine in Biliary Cancer

Nab-Paclitaxel Combo Outperforms Gemcitabine in Biliary Cancer

August 16, 2025

Comparing Treatments for Advanced Esophageal Cancer

August 16, 2025

Immune Checkpoint Inhibitors Show Promise in Unknown Cancers

August 16, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    140 shares
    Share 56 Tweet 35
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    79 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    59 shares
    Share 24 Tweet 15
  • Predicting Colorectal Cancer Using Lifestyle Factors

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

New Metabolic Inflammation Model Explains Teen Reproductive Issues

Mpox Virus Impact in SIVmac239-Infected Macaques

Epigenetic Mechanisms Shaping Thyroid Cancer Therapy

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.